Drugs / AdKCNH2-G628S
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05223725 | Oct 2023 → Aug 2025 | atrial fibrillation | University of Massachusetts, Worcester | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AdKCNH2-G628S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05223725 ↗ |
| Target | KCNH2 | “adenovirus containing the transgene KCNH2-G628S” NCT05223725 ↗ |